Table 5:
Comparison of the glycoprotein IIb/IIIa antagonists
| Abciximab | Tirofiban | Eptifibatide | |
|---|---|---|---|
| Manufacturer | Eli Lilly | Merck | COR Therapeutics |
| Molecule size, datons | 50,000 | 800 | 500 |
| Receptor affinity (KD) | High (5 nmol/L) | Low (15 nmol/L) | Low (120 nmol/L) |
| Plasma high-life, h | 0.2 | 1.5–2 | 2–4 |
| Biologic half-life, h | 12–24 | 1.5–2 | 2–4 |
| Excretion | Renal | Renal/hepatic | Renal |
| Method of reversal | Platelet transfusion | Fresh-frozen plasma, cryprecipitate, platelet transfusion | Fresh-frozen plasma, cryprecipitate, platelet transfusion |